Investing.com -- The U.S. Food and Drug Administration (FDA) has granted approval for an expanded use of Ozempic® (semaglutide) injection, developed by pharmaceutical company Novo Nordisk (NYSE:NVO).

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

The FDA has issued a warning about numerous adverse events, including hospitalizations, stemming from dosing errors and overdoses of compounded semaglutide injectable products, underscoring the risks ...

Patients who are taking GLP-1 medications such as Ozempic, Wegovy, Mounjaro and others could face complications during surgery, recent research has shown. In one study led by UTHealth Houston, more ...

NORTH CAROLINA (WTVD) -- A warning to consumers about fake Ozempic (semaglutide). The FDA issued this alert saying counterfeits have been found in the US drug supply chain. The FDA and the ...

When Tina Jacobson tried to get Ozempic to lose weight, her health insurance provider denied coverage because she was not diabetic. Instead of paying more than $1,000 out of pocket for the Type 2 ...

As part of an effort to improve access to authentic versions of its GLP-1 medications, Novo Nordisk is cutting the cost of its popular diabetes drug Ozempic by nearly half. In an Aug. 18 press release ...

The Food and Drug Administration is warning people to be on the lookout for counterfeit Ozempic, the diabetes drug that many people use off-label for weight loss. The federal agency and Novo Nordisk, ...